Literature DB >> 18508416

A simple bioanalytical assay for determination of montelukast in human plasma: application to a pharmacokinetic study.

Pattana Sripalakit1, Bungon Kongthong, Aurasorn Saraphanchotiwitthaya.   

Abstract

An analytical method based on high-performance liquid chromatographic (HPLC) was developed for the determination of montelukast in human plasma using mefenamic acid as an internal standard. After precipitation of plasma proteins with acetonitrile, chromatographic separation was carried out using a Zorbax Eclipse XDB C8 (150 mm x 4.6 mm i.d., 5 microm) with mobile phase consisted of methanol-acetonitrile-0.04M disodium hydrogen orthophosphate (22:22:56, v/v, pH 4.9). The wavelengths of fluorescence detection were set at 350 nm for excitation and 450 nm for emission. The linearity was confirmed in the concentration range of 5-1000 ng/ml in human plasma. Intra- and inter-day accuracy determined from quality control samples were 101.50 and 107.24%, and 97.15 and 100.37%, respectively. Intra- and inter-day precision measured as coefficient of variation were < or =4.72 and < or =9.00%, respectively. Extraction recoveries of drug from plasma were >48.14%. The protocol herein described was employed in a pharmacokinetic study of tablet formulation of montelukast in healthy Thai male volunteers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508416     DOI: 10.1016/j.jchromb.2008.05.017

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

1.  Development and validation of RP-HPLC method with ultraviolet detection for estimation of montelukast in rabbit plasma: Application to preclinical pharmacokinetics.

Authors:  Om Prakash Ranjan; Usha Y Nayak; Meka Sreenivasa Reddy; Swapnil J Dengale; Prashant B Musmade; Nayanabhirama Udupa
Journal:  J Young Pharm       Date:  2013-11-26

2.  Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.

Authors:  Tarek A Ahmed; Hany M Ibrahim; Ahmed M Samy; Alaa Kaseem; Mohammad T H Nutan; Muhammad Delwar Hussain
Journal:  AAPS PharmSciTech       Date:  2014-03-20       Impact factor: 3.246

3.  Method development and validation of montelukast in human plasma by HPLC coupled with ESI-MS/MS: application to a bioequivalence study.

Authors:  Balasekhara Reddy Challa; Bahlul Z Awen; Babu Rao Chandu; Mukkanti Khagga; Chandrasekhar Bannoth Kotthapalli
Journal:  Sci Pharm       Date:  2010-06-04

4.  Development and validation of LC/MS/MS method for the simultaneous determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study.

Authors:  Essam Ezzeldin; Nisreen F Abo-Talib; Marwa H Tammam; Abdelaaty A Shahat
Journal:  Chem Cent J       Date:  2014-03-11       Impact factor: 4.215

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.